Maja Čikeš
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Transplantation: Methods and Outcomes
- Cardiac pacing and defibrillation studies
- Heart Failure Treatment and Management
- Cardiac Valve Diseases and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiomyopathy and Myosin Studies
- Cardiac Arrhythmias and Treatments
- Acute Myocardial Infarction Research
- Cardiac Arrest and Resuscitation
- Renal Transplantation Outcomes and Treatments
- Viral Infections and Immunology Research
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Disease and Adiposity
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Organ Transplantation Techniques and Outcomes
- Coronary Interventions and Diagnostics
- Advanced MRI Techniques and Applications
- Congenital Heart Disease Studies
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Effects of Exercise
- Cardiac, Anesthesia and Surgical Outcomes
University Hospital Centre Zagreb
2016-2025
University of Zagreb
2016-2025
Brigham and Women's Hospital
2021-2024
Fondazione Toscana Gabriele Monasterio
2024
University of Siena
2024
Shinshu University Hospital
2021
Harvard University
2021
Menarini Group (Germany)
2020
AstraZeneca (Brazil)
2020
Roche (Switzerland)
2020
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their dating.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use care therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical judgment, as...
Vedran Velagic (Croatia), Sami Viskin (Israel)
65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy, and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
Background: Unlike heart failure with reduced ejection fraction, there is no approved treatment for preserved the predominant phenotype in women. Therefore, a greater therapeutic deficit women compared men. Methods: In prespecified subgroup analysis, we examined outcomes according to sex PARAGON-HF trial (Prospective Comparison of ARNI With ARB Global Outcomes Heart Failure Preserved Ejection Fraction), which sacubitril-valsartan and valsartan patients fraction. The primary outcome was...
Nearly half of all patients with heart failure (HF) have a normal left ventricular (LV) ejection fraction (EF) and the condition is termed preserved (HFpEF). It assumed that in these HF due primarily to LV diastolic dysfunction. The prognosis HFpEF almost as severe reduced EF (HFrEF). In contrast HFrEF where drugs devices are proven reduce mortality, there has been limited therapy available documented effects on prognosis. This may reflect encompasses wide range different pathological...
Journal Article Corrected proof Guidelines 2023 ESC for the management of acute coronary syndromes: Developed by task force on syndromes European Society Cardiology (ESC) Get access Robert A Byrne, Byrne (Ireland) Corresponding authors: A. Department and Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Ireland, School Pharmacy Biomolecular Sciences, RCSI University Medicine Health Ireland. Tel: +353-1-2483190, E-mail: robertabyrne@rcsi.ie...
Elevated interleukin (IL)-6 levels have been linked to adverse outcomes in patients with and without baseline cardiovascular disease (CVD).